CHARLESTON, W.Va. -- Closing arguments began Tuesday in a case to decide if C.R. Bard Inc. failed to warn of the dangers associated with vaginal mesh devices the company sold.
Trial in U.S. District Court began for the second time on July 29, after Judge Joseph Goodwin declared a mistrial after three days on July 10.
The trial is the first of more than 20,000 cases pending nationwide to determine if C.R. Bard failed to warn of the dangers associated with the vaginal mesh devices the company sold. Those suing the company allege that the devices weren't suitable for human implantation.
Goodwin has been assigned the vaginal mesh cases as part of federal multidistrict litigation.
Thousands of women contend that the New Jersey-based company used materials in its vaginal mesh products knowing they shouldn't be permanently implanted in humans. The mesh material was designed to support deteriorated pelvic muscles and treat urinary incontinence.
The women claim the mesh degrades and shrinks, requiring replacement and causing other medical problems.
The trial that began July 29 is a lawsuit brought by Donna Cisson. The 54-year-old Georgia woman contends that a device inserted in 2009 caused pelvic and rectal pain, bleeding and bladder spasms and required surgeries to remove it.
Goodwin declared a mistrial early in July after determining jurors wouldn't be able to overlook a doctor's improper testimony.
In May, the judge dismissed a variety of claims, including a manufacturer's defect, by granting summary judgment to the company. He did, however, allow the plaintiff to have a jury decide the claim that the company failed to warn of known dangers.
The judge also determined a jury may award punitive damages, if appropriate, in a separate trial.
U.S. Food and Drug Administration officials estimate that 300,000 women had pelvic organ prolapse surgery in 2010 and that mesh was used in one-third of the procedures.